

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

June 16, 2026  
Date of Report (Date of earliest event reported)

**CervoMed Inc.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-37942  
(Commission  
File Number)

30-0645032  
(I.R.S. Employer  
Identification No.)

20 Park Plaza, Suite 424  
Boston, Massachusetts  
(Address of principal executive offices)

02116  
(Zip Code)

Registrant's telephone number, including area code: (617) 744-4400

Not applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.001 par value	CRVO	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On June 16, 2026, CervoMed Inc. (the “Company”) received a notice of allowance from the United States Patent and Trademark Office related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients with no substantial Alzheimer’s disease-like tau pathology, which is expected to provide intellectual property protection into 2042 (without giving effect to any potential patent term extension).

**Item 9.01 Financial Statements and Exhibits***(d) Exhibits*

<b>Exhibit No.</b>	<b>Description</b>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 18, 2026

**CervoMed Inc.**

By: /s/ William Elder

Name: William Elder

Title: Chief Financial Officer & General Counsel